

SECURITIES AND EXCHANGE COMMISSION

FORM 3

Filing Date: **2013-03-19** | Period of Report: **2013-03-19**
SEC Accession No. [0001181431-13-017965](#)

(HTML Version on secdatabase.com)

REPORTING OWNER

Trias Joaquim

CIK: **1483998**

Type: **3** | Act: **34** | File No.: **001-35837** | Film No.: **13703381**

Mailing Address
C/O ANTHERA
PHARMACEUTICALS, INC.
25801 INDUSTRIAL
BOULEVARD, SUITE B
HAYWARD CA 94545

ISSUER

TETRAPHASE PHARMACEUTICALS INC

CIK: **1373707** | IRS No.: **000000000** | State of Incorporation: **DE** | Fiscal Year End: **1231**
SIC: **2834** Pharmaceutical preparations

Mailing Address
480 ARSENAL STREET
SUITE 110
WATERTOWN MA 02472

Business Address
480 ARSENAL STREET
SUITE 110
WATERTOWN MA 02472
617.715.3600

FORM 3**UNITED STATES SECURITIES AND
EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: 02/28/2011
Estimated average burden
hours per response 0.5**INITIAL STATEMENT OF BENEFICIAL
OWNERSHIP OF SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the
Investment Company Act of 1940

1. Name and Address of Reporting Person Trias Joaquim (Last) (First) (Middle) 960 SEQUOIA AVE (Street) MILLBRAE, CA 94030 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/19/2013	3. Issuer Name and Ticker or Trading Symbol TETRAPHASE PHARMACEUTICALS INC [TTPH]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director <input checked="" type="checkbox"/> 10% Owner ____ Officer (give title below) _____ Other (specify below)	5. If Amendment, Date Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person ____ Form Filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	31,934 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	⁽²⁾	09/27/2020	Common Stock	5,027 ⁽¹⁾	\$2.03 ⁽¹⁾	D	
Employee Stock Option (right to buy)	⁽³⁾	09/10/2019	Common Stock	6,459 ⁽¹⁾	\$0.87 ⁽¹⁾	D	
Series A-1 Convertible Participating Preferred Stock	⁽⁴⁾	⁽⁵⁾	Common Stock	1,379 ⁽⁴⁾	⁽⁴⁾	D	
Series A-2 Convertible Participating Preferred Stock	⁽⁴⁾	⁽⁵⁾	Common Stock	1,800 ⁽⁴⁾	⁽⁴⁾	D	
Series B Convertible Participating Preferred Stock	⁽⁴⁾	⁽⁵⁾	Common Stock	8,068 ⁽⁴⁾	⁽⁴⁾	D	
Series C Convertible Participating Preferred Stock	⁽⁴⁾	⁽⁵⁾	Common Stock	9,388 ⁽⁴⁾	⁽⁴⁾	D	

Explanation of Responses:

1. Reflects a one-for-twenty-nine reverse stock split effected on March 5, 2013.
2. Original grant of 8,938 shares. Subsequently exercised for 3,911 shares. Vested as to an additional 2,234 shares, with further vesting as to an additional 6.25% of the original grant on 6/18/2013 and at the end of each successive three-month period until 6/18/2014.
3. Vested as to 4,306 shares, with further vesting as to an additional 1,076 shares on 6/11/2013 and an additional 1,077 shares on 9/11/2013.
4. Convertible into Common Stock on a 1-for-29 basis without payment of further consideration. Each share will automatically convert into 1/29th of a share of Common Stock upon the closing of the Issuer's initial public offering.
5. Not applicable.

Signatures

/s/ Joaquim Trias

** Signature of Reporting Person

03/19/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.